DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical Visit Post
2 Follicular Lymphoma Market Size Anticipates Growth as the Key Companies Explores Novel Therapeutics Assets Visit Post
3 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
4 Assessing the Opportunities and Challenges in the Oncology Segment Visit Post
5 Evaluating the Present and Future Oncology Market Outlook With Valued Research and Analysis Visit Post
6 ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System Visit Post
7 Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer Visit Post
8 Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Visit Post
9 Abiomed’s Impella ECP; Helius’s PoNS Device; Smart Meter’s iGlucose BGM; XACT’s CT-Guided Percutaneous Procedures; BD’s Veritor At-Home COVID-19 Test; Delfi’s Liquid Biopsy Visit Post
10 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
11 Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea's Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer Visit Post
12 Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer Visit Post
13 MedTech Wrap Up Visit Post
14 Key Pharma Companies Expanding their Arm in the Skin Cancer Segment Visit Post
15 Unity's advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka's candidate; Lilly invests in MiNA; Visit Post
16 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
17 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
18 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
19 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
20 Diagnosis Delays, Ineffective Treatment Options Plaque the Bone Cancer Market Growth Visit Post
21 Amgen a leader in Undruggable Lung Cancer; Verrica's Skin Disease Drug Delays; Fennec's Faith in its Chemotherapy-Induced Hearing Loss Drug; Nexturn Bio's Acquisition of RosVivo Visit Post
22 TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug Visit Post
23 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
24 Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids Visit Post
25 Glioblastoma Multiforme: Advancements in the Treatment Paradigm of the Malignant Condition Visit Post
26 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
27 Adagio Raises $336 M; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy Visit Post
28 Ewing Sarcoma: Key Companies and Emerging Therapies in the Landscape Visit Post
29 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
30 Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities Visit Post
31 Limited Therapeutics Options and A Weak Pipeline: What Lies Ahead in the Cancer Anorexia Market? Visit Post
32 Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application Visit Post
33 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
34 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
35 Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC Visit Post
36 Navigating Through the Treatment Market Landscape of Head and Neck Cancers Visit Post
37 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
38 Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa Visit Post
39 Overwhelming success of Gilead/Kite's Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer Visit Post
40 Rare Cancer Market: A Global Crusade on what is a ‘less common cancer’? Visit Post
41 Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva's $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China Visit Post
42 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
43 Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset Visit Post
44 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
45 Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda's Maribavir; Astellas/Seagen Padcev Visit Post
46 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
47 Progeria: The Rarest Case of Premature Ageing Visit Post
48 Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia Visit Post
49 Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization Visit Post
50 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
51 Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials Visit Post
52 Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline. Visit Post
53 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
54 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
55 Medical Tourism: Road to Affordable and Quality Medical Care Visit Post
56 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
57 Unmet Needs and Emerging Trends in the Acute Respiratory Distress Syndrome Market Landscape Visit Post
58 Improving cancer immunotherapy; Senseonics' Eversense delayed; FDA acknowledges Alkermes' Resubmission; 3D breast ultrasound improves diagnosis Visit Post
59 NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche's bispecific matches Eylea; Research Updates in Leukemia, solid tumors Visit Post
60 Agios' cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial Visit Post
61 13 of the most commonly asked questions about Glioblastoma multiforme, Answered Visit Post
62 Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders Visit Post
63 Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well? Visit Post
64 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
65 KaliVir, Astellas licensing deal; AbCellera's IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Visit Post
66 Roche's quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Visit Post
67 BASE10 Collaboration; Advaxis Public offerings; Takeda's CABOMETYX Japan approval; TheraPharm Acquisition Visit Post
68 Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant's vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic Visit Post
69 Biliary Tract Cancer: Emerging Players in the Market Transforming the Treatment Landscape Visit Post
70 Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M Visit Post
71 Lung Cancer and its Increasing Global Burden Visit Post
72 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
73 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
74 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
75 7 Most Common Myths About Breast Cancer Demystified Visit Post
76 Key Facts To Know About Triple-Negative Breast Cancer In The Breast Cancer Awareness Month Visit Post
77 Breast Cancer: Understand your breasts, recognize the symptoms Visit Post
78 Market Drivers and Barriers That Will Shape The NMIBC Market In The Next Ten Years Visit Post
79 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
80 How do we curb the Opioid Epidemic? Visit Post
81 Key Companies To Keep an Eye on for Pipeline Therapies in Osteosarcoma Market in the Next Decade Visit Post
82 Pitfalls of Current Osteosarcoma Treatment Approaches Visit Post
83 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
84 Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing Visit Post
85 Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On Visit Post
86 Huge Unmet Needs in the Glioblastoma Multiforme Treatment Market Driving the Market Size Growth Visit Post
87 Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome's Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks Visit Post
88 Cervical Cancer Market Has A Lot Going On Under The Hood Visit Post
89 Lilly's COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian's CD40L cell therapy Visit Post
90 While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals Visit Post
91 Preventing Cervical Cancer Through Screening And HPV Vaccines Visit Post
92 Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates Visit Post
93 Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse Visit Post
94 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
95 Healthcare Delivery System: What lies in the future? Visit Post
96 Moderna's COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates Visit Post
97 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
98 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
99 Enough Of Wasting Away From Cancer: Companies Gear Up To Tackle Cachexia Visit Post
100 AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid's DMD gene therapy trial Visit Post
101 Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai's Collaboration; A new study on averting heart attack Visit Post
102 Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update Visit Post
103 Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates Visit Post
104 Small Cell Lung Cancer Market Booms with an Influx of Companies and Robust Pipeline Visit Post
105 Top 5 Cancers Creating Major Challenge To The Global Healthcare System Visit Post
106 Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab's result; Orca raises $192M Visit Post
107 Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL Visit Post
108 One of the leading causes of blindness, and a sight-threatening disease, Uveitis, now has novel treatment approaches in its pipeline Visit Post
109 Precision Medicine: An emerging approach to conventional treatment Visit Post
110 Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ's anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost Visit Post
111 Altering the course of Ovarian cancer with emerging therapies in the horizon Visit Post
112 Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses Visit Post
113 Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines Visit Post
114 Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19 Visit Post
115 Soft Tissue Sarcoma Market size to increase with a CAGR of 6.47% – Emerging therapies and Increasing Incidence form major market drivers Visit Post
116 JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19 Visit Post
117 Soft Tissue Sarcoma Treatment Market: Present treatment approaches and Unmet Needs Visit Post
118 Soft Tissue Sarcoma: A rare malignancy Visit Post
119 Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust Visit Post
120 J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug Visit Post
121 Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma Visit Post
122 First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed's shares Soares Visit Post
123 Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102 Visit Post
124 Malignant Pleural Mesothelioma Upcoming Therapies Visit Post
125 Malignant pleural mesothelioma market: Elusive treatment approaches and Poor diagnosis Visit Post
126 Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M Visit Post
127 Marijuana as a treatment approach Visit Post
128 Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO Visit Post
129 GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3 Visit Post
130 Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval Visit Post
131 Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition Visit Post
132 Acquisition of ArQule; Synthorx; and Zentalis nabs a raise Visit Post
133 Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval Visit Post
134 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
135 Metastatic Pancreatic Cancer Market Size: Emerging therapies, Unmet needs and Forecast analysis Visit Post
136 Non-small cell lung cancer emerging therapies Visit Post
137 AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy Visit Post
138 Non-Small Cell Lung Cancer Market: Treatments and Market Forecast Visit Post
139 AZ announces positive results for durvalumab and tremelimumab; FDA nods to extend LILETTA’s use to prevent pregnancy; Gilead, Glympse Bio teams up to advance NASH clinical development Visit Post
140 Refractory Metastatic Melanoma Market Visit Post
141 Metastatic HER2-Positive Breast Cancer Infographic Visit Post
142 Rapt Therapeutics files IPO; Novartis stakes $80M for NASH Visit Post
143 New Therapeutic advances that have shifted the Breast cancer market scenario Visit Post
144 HR-positive/ HER2-negative Breast Cancer Market Insights: Upcoming Therapies and Market Analysis Visit Post
145 Roche’s Tecentriq combo proves effective in Bladder cancer Visit Post
146 STipe raises USD 22M; FDA approves Darzalex for multiple myeloma Visit Post
147 Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial Visit Post
148 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
149 AlivaMab collaborates with Janssen for antibody discovery; Lundbeck acquires Alder BioPharmaceutical; Helsinn and Mundipharma announce China approval of Akynzeo Visit Post
150 How HR+/ HER2-Breast Cancer emerging drugs will transform the market? Visit Post
151 Global HR+/ HER2- Breast Cancer Market Scenario Visit Post
152 Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership  Visit Post
153 Daiichi Sankyo fuels commercialization of DS-8201 in Japan; Roivant Sciences transfers its biotech stake for USD 3 Billion; FDA, EMA accepts marketing of Allergan’s abicipar Visit Post
154 Metastatic HER2-Positive Breast Cancer Visit Post
155 Driving factors boosting the Hepatocellular Carcinoma Market Visit Post
156 Helsinn out licenses Pracinostat in South America Visit Post
157 HiFiBio raises USD 67 M; FDA drafts new guidelines for Breast cancer trials; Harbour BioMed teams up with Pharmaceutical Product Development Visit Post
158 What to expect in the Coming Years for Hairy Cell Leukemia Therapy landscape? Visit Post
159 Imfinzi fails. What’s next in Non-small cell lung cancers Market Scenario? Visit Post
160 Juvenescence nets USD 100M; Sarepta DMD drug faces rejection Visit Post
161 Chemotherapy-Induced Peripheral Neuropathy Market Trends Visit Post
162 Turalio gets FDA approval; Sosei Heptares, Takeda forms an R&D pact Visit Post
163 FDA approval for Nubeqa; Biodesix, Immodulon collaborates on Cancer treatment; Cancer asset rights to Alligator Bioscience Visit Post
164 CHPM’s positive approval for 13 Medicines; NICE approval for AstraZeneca’s Olaparib; Exact Sciences to buy Genomic Health Visit Post
165 Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M; FDA approval for Ruxience for leukaemia Visit Post
166 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
167 Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M Visit Post
168 Cutaneous T-cell lymphoma Market Outlook Visit Post
169 EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline Visit Post
170 FDA's approval to Pfizer’s Zirabev; Launch of Century Therapeutics; Imbruvica's recommendation from CHMP Visit Post
171 Zejula's priority review; Erytech Pharma's new facility; good news for Krystal Visit Post
172 The Business Cocktail Visit Post
173 Notizia Visit Post
174 World Brain Tumor Day Visit Post
175 The Business Cocktail Visit Post
176 Notizia Visit Post
177 Global Neuroendocrine Tumor Market Outlook Visit Post
178 WORLD NO TOBACCO DAY Visit Post
179 The Business Cocktail Visit Post
180 Notizia Visit Post
181 The Business Cocktail Visit Post
182 Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M Visit Post
183 AstraZeneca-Daiichi’s results; Novartis remunerates; Pfizer to acquire Therachon; Gilead & Goldfinch Bio collaboration Visit Post
184 World Ovarian Cancer Day | 2019 Visit Post
185 Notizia Visit Post
186 Ovarian Cancer Treatment Drugs and Unmet Needs Visit Post
187 The Business Cocktail Visit Post
188 Notizia Visit Post
189 Can commoners afford to spend million dollars on GENE Therapy? Visit Post
190 Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal Visit Post
191 Notizia Visit Post
192 Gene Therapy in Oncology: Innovation to Commercialization Visit Post
193 Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion Visit Post
194 The promising Pipeline for Gene Therapy In Oncology Visit Post
195 Notizia Visit Post
196 Notizia Visit Post
197 Multiple Myeloma Day Visit Post
198 The changing landscape of Multiple Myeloma therapies market Visit Post
199 Notizia Visit Post
200 ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness Visit Post
201 A helping hand in treatment of CRC Visit Post
202 What is Cholangiocarcinoma (CCA)? Visit Post
203 Notizia Visit Post
204 Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets Visit Post
205 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
206 Genentech remunerates Xencor; XPrize upraises fund; GSK gambles Visit Post
207 Neuroendocrine Tumors (NETs) Visit Post
208 Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal Visit Post
209 Biodesix collaborates with MRM; Avoiding flu with an antibody; Soliris clears trial Visit Post
210 Molecular Profiling Could Help in Early Lung Cancer Detection: Study Visit Post
211 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
212 Notizia Visit Post
213 Cervical cancer Visit Post
214 Virtual Reality Maps Helps Doctors Understand Cancer Tumor Structure Visit Post
215 Highly mutated cancers respond better to immune therapy Visit Post
216 Notizia Visit Post
217 Triple Negative Breast Cancer Responds to TINAGL Therapy Visit Post
218 Apollomics raises; Pear Therapeutics raises $64M; Lilly to acquire Loxo Visit Post
219 Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod Visit Post
220 Machine Learning Models to Help Predicting Cancer Symptoms, Plan Treatment Visit Post
221 Cervical cancer: What you need to know Visit Post
222 HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing Visit Post
223 66 Year Ohio Woman Becomes Cancer Free, Thanks to CAR T Cell Therapy Visit Post
224 Now, Artificial Intelligence to Accurately Identify Cancer Cells Visit Post
225 Gold Nanoparticles May Soon Treat Prostate Cancer Visit Post
226 Cancer Cells Trick Body’s Immunity to Survive against Treatment Visit Post
227 Notizia Visit Post
228 Scientists Now Target Attacking Evolution Process of Cancer Cells Visit Post
229 Chemotherapy as a treatment for Cancer?  Visit Post
230 Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates Visit Post
231 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
232 Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal Visit Post
233 Notizia Visit Post
234 Virus, the Cancer Therapy of the Future Visit Post
235 Triple Negative Breast Cancer Visit Post
236 Gordon and Betty Moore Foundation gives $85M; Omeicos raises; Sanofi signs deal; Lilly grabs Visit Post
237 FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan Visit Post
238 Lung Cancer Infographic Visit Post
239 150 Year Old Drug Indicates Potential of Future Cancer Therapy Visit Post
240 The risk of solid cancer after chemotherapy Visit Post
241 Notizia Visit Post
242 INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER Visit Post
243 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
244 Notizia Visit Post
245 Is Gene Therapy the Next Cancer Treatment Revolution?  Visit Post
246 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
247 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
248 The novel therapy for brain cancer treatments Visit Post
249 Precautions for Breast Cancer Visit Post
250 Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner Visit Post
251 BREAST CANCER AWARENESS MONTH Visit Post
252 Companion Diagnostics Visit Post
253 Notizia Visit Post
254 Researchers Turn towards Light to Solve Lung Cancer Puzzle Visit Post
255 Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research Visit Post
256 Snippet Visit Post
257 Biologic Parallel – A Perky Future Ahead Visit Post
258 Notizia Visit Post
259 Pancreatic Cancer Treatment to Stride Beyond Chemotherapy Visit Post
260 Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M Visit Post
261 Snippet Visit Post
262 Notizia Visit Post
263 Neuroendocrine tumors (NETs): The complex group of tumors Visit Post
264 Now, Nanoparticles for Cancer Treatment Visit Post
265 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
266 Commercial Visit Post
267 Clinical Visit Post
268 AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval Visit Post
269 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
270 China Preparing for Pharma Big Bang: Is this Alarm Bell for US, Euro Pharma Giants? Visit Post
271 Japan Manages to Stand Apart from Global Hepato Cellular Carcinoma Crowd Visit Post
272 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
273 Snippet Visit Post
274 Kalydeco got approved; Opdivo for SCLC; FDA approved for pain relief; GC4419 obviates Visit Post
275 KEY CLINICAL OUTCOMES Visit Post
276 Personalized Medicine Approach: An Upholding Paradigm for a Promising and futuristic Patient Centric Health Care Visit Post
277 Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup Visit Post
278 Progenics got FDA Approval; Curcumin to cancer cells Visit Post
279 Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration Visit Post
280 Snippet : Acute lymphoblastic leukemia Visit Post
281 Business Cocktail Visit Post
282 Commercial Outcomes - Novartis Visit Post
283 Oncology Highlights - 30/07/2018 Visit Post
284 Predicting risk of Acute Myeloid Leukemia (AML) in healthy individuals Visit Post
285 NF-κB Inhibitors- A Promising Future Visit Post
286 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
287 Business Cocktail Visit Post
288 Hematopoietic Stem Cell Transplantation Visit Post
289 Takeda buys Shire in a deal worth USD 62 billion Visit Post
290 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
291 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
292 Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients Visit Post
293 STAT INHIBITORS- Highly active Pipeline Visit Post
294 Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs Visit Post
295 Takeda acquisition on Shire raises its share by 25 percent Visit Post
296 Business Cocktail Visit Post
297 Business Cocktail Visit Post
298 New method for classification of CNS tumors Visit Post
299 Notizia Visit Post
300 Notizia Visit Post
301 The Business Cocktail : Latest Pharma deals Visit Post
302 CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff Visit Post
303 Immune Checkpoint Activators (ICA): Dynamic Therapeutic Targets Visit Post
304 Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers Visit Post
305 Business Cocktail Visit Post
306 Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon Visit Post
307 Adapsyn signed; Evolus filed; BioNTech signed a deal; Nordisk’s deal Visit Post
308 Notizia Visit Post
309 Business Cocktail Visit Post
310 Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln's anti-malarial drug Visit Post
311 Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allergan on women’s health Visit Post
312 KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha Visit Post
313 Targeting cancer through CD40 agonists -A promising future Visit Post
314 Chemists may help solve the air-pollution health crisis Visit Post
315 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
316 Business Cocktail Visit Post
317 AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes Visit Post
318 Novo petitions FDA;J&J invests; Xarelto’s trial; Roche's Tecentriq Visit Post
319 C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents Visit Post
320 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
321 Isocitrate dehydrogenase (IDH) inhibitors– Emerging Anti-Cancer Therapeutics Visit Post
322 Oral Mucositis – A Common Cancer Therapy Adverse Reaction Visit Post
323 Business cocktail Visit Post
324 Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval Visit Post
325 HDAC (Histone Deacetylase) Inhibitors – A Promising Anti-Cancer Target Visit Post
326 CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M Visit Post
327 Cancer Globally (Vol. 1, Issue 1) Visit Post
328 Bruton's Tyrosine Kinase (BTK) Inhibitors An Emerging Therapeutic Target Visit Post
329 Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults Visit Post
330 PARP Inhibitors making inroads into Ovarian Cancer Visit Post
331 Business CockTail Visit Post
332 CDK 4/6 Inhibitors- The Changing Paradigm for Breast Cancer Treatment Visit Post
333 Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter Visit Post
334 Takeda scores; PhRMA launches; Valeant's Obagi; Ex-Novo executive signs Visit Post
335 Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent gets struck down Visit Post
336 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
337 Takeda knocks Velcade; FDA nod awaited; Novartis gets approval; Astellas UK dodges; Haegarda set for launch Visit Post
338 Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports Visit Post
339 J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials Visit Post
340 Sanofi invests; ICER pitches; $6M in NIH; Pfizer, Roche cancer drug pricing Visit Post
341 New cancer drug tested in mice may benefit certain leukaemia patients Visit Post
342 AZ offloads; Pfizer's deal; Takeda’s work on plant; Germany's doc payment Visit Post
343 Gut bacteria can stop cancer drugs from working Visit Post
344 Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins; Alecensa trounces Visit Post
345 Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal Visit Post
346 FDA grants accelerated approval to pembrolizumab Visit Post
347 Novartis, slammed by Korean scandal; FDA tweaks; Dendreon eyes; Amgen adds Visit Post
348 Cutaneous Squamous Cell Carcinoma Market & pipeline Visit Post
349 World Ovarian Cancer Day Visit Post
350 Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal Visit Post
351 FDA Approves; AZ nabs; Nordisk settles; Novartis pays Visit Post
352 Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A Visit Post
353 Non-Hodgkin Lymphoma: “Malignant Growth of White Blood Cells” Visit Post
354 Chemotherapy-Induced Nausea and Vomiting Side effects Visit Post
355 Drug shortage; Fujifilm invests; Cobra Biologics to pump $19M; The world's most pricey drugs Visit Post
356 The Snippet: Targeting metabolism in Renal Cell Carcinoma Visit Post
357 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
358 Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B; Fresenius in buyout talks Visit Post
359 Dengvaxia study; Opdivo racks up; FDA issues plant; Teva's Rimsa fraud; Mission bags Fox grant Visit Post
360 CRISPR finds faults in previous researches Visit Post
361 Valeant's asset-sale; Sanofi coughs up $19.8M; Sanofi's Genzyme; India's Alkem; GSK’s inhalers Visit Post
362 DNA typos to blame for most Cancer Mutations Visit Post
363 Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings Visit Post
364 AKT Inhibitors: A potential Cancer Immunotherapy Target Visit Post
365 Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns Visit Post
366 GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss Visit Post
367 Colorectal Cancer Awareness Month Visit Post
368 New biomarkers improve standard screening in Pancreatic Cancer Visit Post
369 New biomarkers for screening in Pancreatic Cancer Visit Post
370 Business Cocktail Visit Post
371 NPPA slams; Japan Joins Trump; PCI Pharma Announces Expansion; Merck opens plant; Mylan and Biocon win Visit Post
372 Colorectal Cancer Market Analysis and Market Forecast Visit Post
373 Clinigen and Eisai team up; Sanofi, Lonza enter; Fidia to acquire; J&J completes acquisition Visit Post
374 Colony Stimulating Factor 1 Receptor (CSF1R) and Its connection with Memory Retention Visit Post
375 PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch Visit Post
376 Diminishing pipeline of Galectin Inhibitors Visit Post
377 TRAIL Receptor Agonists: Emerging target therapies against Cancer Visit Post
378 OncoTrack develops new biomarkers for colon cancer Visit Post
379 SEC scrutinizes; Acacia meets endpoint; Axovant's dementia drug; Novartis expands; Aurobindo responds Visit Post
380 Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation Visit Post
381 FDA approves; Sun Pharma Recalls; Mezzion filed; Sanofi’s antibody to treat Visit Post
382 Statistical Insight on Some Common Cancers Visit Post
383 Subtypes of cervical cancer identified Visit Post
384 Prostate Cancer: Metastases leading to increased incidence in the USA Visit Post
385 FDA accepts; Keytruda takes lead; M Pharmaceutical develops; Merck Deploys Palantir Visit Post
386 Microbiome- A Living Therapy from Guts to Cancer Visit Post
387 Biosimilars: A benchmark in Pharmaceutical Business Visit Post
388 Aurobindo takes top generic spot; Valeant unloads Dendreon; Ipsen strikes $1B deal; Takeda shells out $5.2B Visit Post
389 mTOR Inhibitors-Emerging therapy in various therapeutic areas Visit Post
390 Pfizer uses; FDA approves; EMA approves; Mylan launches Visit Post
391 Ovarian Cancer: The Silent Killers Visit Post
392 Most Common Cancers Visit Post
393 CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective Visit Post
394 Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal; Astellas scouts pipeline Visit Post
395 Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat Visit Post
396 The next generation of 'weaponized antibody' therapies Visit Post
397 EC grants; Pfizer cuts; 27 medicines sold; Keytruda nabs Visit Post
398 High Risk Smoldering Multiple Myeloma Visit Post
399 NgAgo gene-editing, claiming to be a better alternative to CRISPR gene editing, falls into a controversy in peer-reviewed papers Visit Post
400 Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant Visit Post
401 Phosphoinositide 3-Kinase (PI3k) Inhibitors: Emerging target therapies against Cancer Visit Post
402 CRISPR gene-editing tested in a person for the first time Visit Post
403 Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika Visit Post
404 Estrogen Receptor Positive Breast Cancer: Market Outlook Visit Post
405 Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration; UPS to Acquire Marken Visit Post
406 Biosimilar Market in India Visit Post
407 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
408 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
409 Liquid Biopsy: Revolutionary Technique for Cancer Diagnosis Visit Post
410 Merck Focuses its Research on Hard to Treat Cancers Visit Post
411 Cervical Cancer: Current Scenario Visit Post
412 Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Visit Post
413 PI3Kγ- a molecular switch that controls immune suppression Visit Post
414 HER2 Expression and its Dynamic Functional States Visit Post
415 Novel Genetics Biomarker found by a Group of Researchers May Offer Novel Treatment Approach for Cancer Visit Post
416 Sun Pharma forms partnership; Pfizer and DCRI collaborate; Avara Acquires AZ; ASLAN Pharmaceutical’s Collaboration; Amgen and Servier partnership Visit Post
417 Treatment for esophageal cancer; FDA bans soaps; Dr Reddy's Launches; Cipla Gets Approval Visit Post
418 Recent Pharma Developments related to Immune Checkpoint Activators Visit Post
419 Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug Visit Post
420 Identity Crises Faced by a Venerable Brain-Cancer Cell Line Visit Post
421 PD-1 and PDL-1 Immune Check Point Inhibitors: A Prodigious Revolution in Cancer Treatment Visit Post
422 Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer Visit Post
423 The Curious Case of CRISPR Technology Visit Post
424 Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Patent fight Visit Post
425 Collaboration provides new insight into cancer treatment Visit Post
426 Pharm Delve Cognizance Visit Post
427 Turning your own skin cells into cancer-killing machines Visit Post
428 A promising immune-stimulating target Visit Post
429 Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2020 Visit Post
430 Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
431 Acute Myeloid Leukemia- Market Insights, Epidemiology & Forecast Visit Post
432 Antibody-Drug Conjugate Market Insight Visit Post
433 PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 Visit Post
434 LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 - A DelveInsight Report Visit Post
435 Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast Visit Post
436 Zemplar Drug Insights, 2016 Visit Post
437 Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Visit Post
438   Pancreatic Cancer-Pipeline Insights, 2016 Visit Post
439 Peripheral Lung Cancer Pipeline Insights, 2016 Visit Post
440 Small interfering RNA (siRNA) Therapeutics Visit Post
441 “Endometrial Cancer - Pipeline Insights, 2015”- A DelveInsight’s Report Visit Post
442 PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 - A DelveInsight Report Visit Post
443 Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 Visit Post
444 Oral Mucositis Pipeline Insights, 2015- A DelveInsight Report Visit Post
445 Cytotoxic T lymphocyte-associated antigen-4 Market Forecast & Analysis Visit Post
446 DelveInsight’s Oncology based Reports, 2015 Visit Post
447 DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports Visit Post
448 Chimeric Antigen Receptor T cell Therapy Market Visit Post
449 Chimeric Antigen Receptor T-cell Therapy Landscape Visit Post
450 Telomerase Inhibitors – An Anti Cancer Approach Visit Post
451 PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015 Visit Post
452 Antibody-Drug Conjugate and Big Pharmaceutical Companies Visit Post
453 Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now! Visit Post
454 Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis Visit Post
455 Antibody-Drug Conjugates Market Outlook, 2015 Report Visit Post
456 Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy Visit Post
457 DelveInsight’s Oncology based Gene Therapy Reports Visit Post
458 Metastatic Prostate Cancer-Pipeline Insights, 2014 Visit Post
459 Oncology Therapeutics Making Big in Coming Years Visit Post